Lucid Diagnostics Inc. - Common Stock (NQ:LUCD)

0.6423 -0.0078 (-1.20%)

Delayed Quote Updated: 11:16 AM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Lucid Diagnostics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

What's going on in today's after hours session ↗

October 01, 2026

Via Chartmill

Which stocks are experiencing notable movement on Thursday? ↗

October 01, 2026

Via Chartmill

3 Key Reasons to Buy This Huge Turnaround Story That's Gaining Traction ↗

October 01, 2026

After shedding roughly 75% of its value during the past three years, it might not take much improvement for Stellantis' stock price to pop.

Via The Motley Fool

Topics Electric Vehicles

Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript ↗

August 20, 2026

Revenue jumped 17% as company shifts focus to higher-reimbursement opportunities.

Via The Motley Fool

Topics Earnings

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

A Glimpse of Lucid Diagnostics's Earnings Potential ↗

May 13, 2025

Via Benzinga

Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth ↗

August 15, 2026

Lucid Diagnostics (NASDAQ:LUCD) is positioning its EsoGuard test as a non-invasive tool to identify Barrett’s Esophagus, a precancerous condition associated with esophageal cancer, while it awaits a...

Via MarketBeat

Topics Death

Lucid Diagnostics Q2 Earnings Call Highlights ↗

August 13, 2026

Lucid Diagnostics (NASDAQ:LUCD) reported second-quarter revenue of $1.5 million on 2,770 EsoGuard tests, as the company continued to target quarterly test volume of roughly 2,500 to 3,000 tests while...

Via MarketBeat

Topics Earnings

Lucid Diagnostics Q2 2026 Earnings Call: Complete Transcript ↗

August 13, 2026

Lucid Diagnostics (NASDAQ:LUCD) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For...

Via Benzinga

Topics Earnings

PAVmed (PAVM) Q4 2025 Earnings Transcript ↗

May 15, 2026

PAVmed (PAVM) Q4 2025 Earnings Transcript

Via The Motley Fool

LUCD Q1 2026 Earnings Transcript ↗

May 14, 2026

LUCD Q1 2026 Earnings Transcript

Via The Motley Fool

Lucid Diagnostics Q1 Earnings Call Highlights ↗

May 14, 2026

Lucid Diagnostics (NASDAQ:LUCD) reported first-quarter 2026 EsoGuard test volume above its pre-Medicare target range, while management said it continues to await a Medicare local coverage determination...

Via MarketBeat

Topics Earnings

Lucid Diagnostics (LUCD) Earnings Transcript ↗

March 26, 2026

Lucid Diagnostics (LUCD) Earnings Transcript

Via The Motley Fool

PAVM Stock Shot Up Over 250% Today – What’s The Deal With The Department of Veterans Affairs? ↗

January 21, 2026

The company’s subsidiary, Lucid Diagnostics, secured a contract from the U.S. Department of Veterans Affairs to provide its EsoGuard Esophageal DNA Test for the detection of esophageal precancer.

Via Stocktwits

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

September 09, 2025

Via Benzinga

LUCID DIAGNOSTICS INC (NASDAQ:LUCD) Reports Q2 2025 Earnings In Line with Estimates, Narrower Loss Than Expected ↗

August 13, 2025

Lucid Diagnostics (LUCD) Q2 2025 results: Revenue $1.16M, EPS -$0.10, beating estimates. Processed 2,756 EsoGuard tests, maintains $30M+ cash. Stock up 2.26% pre-market.

Via Chartmill

LUCD Reports Results ↗

August 13, 2025

Via The Motley Fool

Topics Intellectual Property

SAIC, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

June 02, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 02, 2025

Via Benzinga

Earnings Scheduled For August 13, 2025 ↗

August 13, 2025

Via Benzinga

Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket ↗

June 02, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

May 23, 2025

Via Benzinga

Lucid Diagnostics: DNA Testing To Get Medicare Coverage, Driving Volumes, Says Bullish Analyst ↗

April 11, 2025

A Needham analyst predicts that Lucid Diagnostics (NASDAQ: LUCD) will see a surge in testing volumes with expected Medicare reimbursement approval.

Via Benzinga

Top stock movements in today's session. ↗

April 10, 2025

Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Earnings Scheduled For May 14, 2025 ↗

May 14, 2025

Via Benzinga

Top movers analysis in the middle of the day on 2025-04-10: top gainers and losers in today's session. ↗

April 10, 2025

Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 10, 2025

Via Benzinga

These stocks are gapping in today's session ↗

April 10, 2025

Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.